Beranda › Purpura Trombositopenik Idiopatik › North Carolina
Uji klinis Purpura Trombositopenik Idiopatik di North Carolina
7 studi untuk Purpura Trombositopenik Idiopatik mencari peserta di lokasi di North Carolina.
Kota di North Carolina
Teks studi resmi (Bahasa Inggris)
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Duke University Hospital, Durham
- East Carolina University, Greenville
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT06722235Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia
- East Carolina University, Greenville
Menerima pesertaFase 2
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT07095127A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
- East Carolina University, Greenville
Menerima pesertaFase 3
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT07059000A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Duke University Hospital, Durham
- East Carolina University, Greenville
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06948318Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
- Universtity of North Carolina at Chapel Hill, Chapel Hill
Menerima pesertaFase 1
Usia 18 hingga 85 · Semua jenis kelamin · Diperbarui 22 Jul 2026 · NCT06371417Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- East Carolina University, Greenville
Menerima pesertaFase 2
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 12 Mei 2026 · NCT05070845A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
- Duke University Medical Center, Durham
- Brody School of Medicine at East Carolina University, Greenville
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Mei 2026 · NCT06544499Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.